Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 16/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.49 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.48 |
| ▸ | ITGB6 | P18564 | 4/20 | 0.44 |
| ▸ | ITGB8 | P26012 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5734872 | 0.85 | ITGB3 (0.64) | ITGAVITGB3ITGA2BITGB5ITGB6 | |
| SCHEMBL6371795 | 0.74 | ITGB3 (0.56) | ITGAVITGB3ITGA2BITGB5ITGB6 | |
| SCHEMBL5746865 | 0.72 | ITGB3 (0.63) | ITGAVITGB3ITGA2BITGB5ITGB6 | |
| SCHEMBL5736678 | 0.72 | ITGB3 (0.64) | ITGAVITGB3ITGA2BITGB5ITGB6 | |
| SCHEMBL6421564 | 0.71 | ITGAV (1.00) | ITGAVITGB3ITGA2BITGB5ITGB6 | |
| SCHEMBL6359531 | 0.71 | ITGAV (1.00) | ITGAVITGB3ITGA2BITGB5ITGB6 | |
| SCHEMBL6421303 | 0.71 | ITGAV (1.00) | ITGAVITGB3ITGA2BITGB5ITGB6 | |
| SCHEMBL6421097 | 0.69 | ITGAV (0.79) | ITGAVITGB3ITGA2BITGB5ITGB6 | |
| SCHEMBL7448931 | 0.68 | ITGAV (0.82) | ITGAVITGB3ITGA2BITGB5ITGB6 | |
| SCHEMBL6421874 | 0.68 | ITGAV (0.85) | ITGAVITGB3ITGA2BITGB5ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165036-A1 | Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165036-A1 | Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists | ITGB5, ITGAV, ITGB1 | ITGAV 2/4885ITGB3 4/4885ITGA2B 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.